EAPs: Market access outside of the US and Western Europe

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean.

Market access strategies in many international markets do not function the same way as they do in the US or Western Europe and require a different approach. Zorlular explains how EAPs can drive revenue for pharmaceutical companies from international unlicensed markets, but that most importantly EAPs allow patients access to life-altering novel medicines.

What’s more, he says, EAPs can also help shape the biotech space by supporting the opportunity for RWD collection outside of the clinical trial setting and build momentum with local payers, regulators, and the medical community.

You can listen to episode 179a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!